Estrogen use among nursing home residents with a diagnosis of Parkinson's disease

Movement Disorders

Volumn 15, Issue 6, 2000, Pages 1119-1124

  Fernandez, Hubert H ^a,b,c   Lapane, Kate L ^b  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Behavior; Dementia; Estrogen; Long term care; Nursing home; Parkinson's disease; Pharmacoepidemiology

Indexed keywords

ANTIDEPRESSANT AGENT; ESTROGEN;

AGED; ARTICLE; BEHAVIOR; CLINICAL OBSERVATION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DATA BASE; DEMOGRAPHY; DEPRESSION; DRUG EFFECT; DRUG USE; FEMALE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MOTOR PERFORMANCE; NURSING HOME; PARKINSON DISEASE; PRIORITY JOURNAL; RACE DIFFERENCE; RESIDENT;

ACTIVITIES OF DAILY LIVING; AGED; COGNITION; CROSS-SECTIONAL STUDIES; DEMENTIA; DEPRESSION; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NURSING HOMES; OSTEOPOROSIS, POSTMENOPAUSAL; PARKINSON DISEASE; POPULATION SURVEILLANCE; UNITED STATES;

EID: 0033693347     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200011)15:6<1119::AID-MDS1009>3.0.CO;2-0     Document Type: Article

References (96)

1. Oestrogens and extrapyramidal system
2. Neuroleptiques, parkinsonism, et schizophrenia
3. Neuroleptic-induced extrapyramidal symptoms
4. Estrogens and the pathophysiology of Parkinson's disease
5. Estrogens and Parkinson's disease
6. Estrogens, dopamine and dyskinesia
7. Estrogens in tardive dyskinesia in male psychiatric patients
8. Estrogen treatment of dyskinetic disorders
9. Estrogen and dyskinesia
10. Interaction between estradiol prolactin and striatal dopaminergic mechanisms
11. Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys
12. Hormones and Parkinson's disease
13. The effect of estrogen replacement on early Parkinson's disease
14. Menstrual-related fluctuations in Parkinson's disease
15. Menstrual related fluctuations in Parkinson's disease
16. Menstrual-cycle related changes in Parkinson's disease
17. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period
18. Chorea gravidarum
19. Ovarian steroid hormones and cerebral function
20. Neurology of sex steroids and oral contraceptives
21. Chorea induced by oral contraceptives
22. Direct effect of 17 B-esradiol on striatum: Sex differences in dopamine release
23. Estrogen as a neuroprotectant against MPTP-induced neurotoxiaty in C57/B1 mice
24. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice
25. Acute stimulatory effect of estradiol on dopaminergic synthesis
26. Modulation by estradiol and progesterone of the GTP effect on striatal D2 dopamine receptors
27. Estradiol in the striatum: Effects on behavior and dopamine receptors but no evidence for membrane steroid receptors
28. Estrogen on tyrosine hydrolase in mRNA in cultured embryonic rat mesencephelon
29. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model
30. Short-term effects of high dose 17 B-estradiol in postmenopausal PD patients: A crossover study
31. Effects of female sex steroids on Parkinson's disease in postmenopausal women
32. Estrogen use and verbal memory in healthy postmenopausal women
33. Estrogen replacement therapy and memory in older women
34. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women
35. An evaluation of psychologic effects of sex hormone administration in aged women: Results after six months
36. Replacement therapy and piperazine oestrone sulfate ('Harmogen') and its effect on memory
37. Oestrogen therapy and the menopausal syndrome
38. The influence of oestrogens on the well being and mental performance in climateric and postmenopausal women
39. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women
40. Effects of estrogen on memory function in surgically menopausal women
41. A case-control study of Alzheimer's disease in Australia
42. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and non-demented control subjects
43. Estrogen deficiency and risk of Alzheimer's disease in women
44. Lack of postmenopausal estrogen replacement therapy and the risk of dementia
45. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
46. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The baltimore longitudinal study of aging
47. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
48. In vivo effects of estrone sulfate on the central nervous system-senile dementia (Alzheimer's type)
49. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double blind study
50. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer's type
51. A population based investigation of Parkinson's disease with and without dementia: Relationship to age and gender
52. Dementia in Parkinson's disease
53. Postmenopausal estrogen use and Parkinson's disease with and without dementia
54. Estrogen replacement therapy and cognitive function in older women
55. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women
56. The effect of castration and peroral estrogen therapy on some psychological functions
57. Estrogen improves psychological function in asymptomatic postmenopausal women
58. Alzheimer's disease: A study of epidemiological aspects
59. Risk factors for clinically diagnosed Alzheimer's disease: A case-control study of an Italian population
60. A case-control study of Alzheimer's disease
61. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
62. Estrogen replacement and response to fluoxetine in a multi-center geriatric depression trial
63. When does estrogen replacement therapy improve sleep quality?
64. Estrogen therapy for severe persistent depression in women
65. Estrogen in the treatment of depression: Neuropharmacological mechanisms
66. Potentiating effect of estrogen in a patient with treatment-resistant depression
67. Estrogen for postnatal depression
68. Role of estrogen in postmenopausal depression
69. Estrogen use and depressive symptoms in postmenopausal women
70. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence
71. Benefits and risks of hormone/estrogen replacement
72. The SAGE databases: Introducing functional outcomes in geriatric pharmaco-epidemiology
73. Characteristics of the SAGE database: A new resource for research on outcomes in long-term care
74. Designing the national resident assessment instrument for nursing homes
75. Validity of diagnostic and drug data in standardized nursing home resident assessments; potential for geriatric pharmacoepidemiology
76. MDS cognitive performance scale
77. The structure of social engagement among nursing home resident
78. The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set
79. Validation of the minimum data set cognitive performance scale: Agreement with the mini mental state examination
80. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS)
81. Effects of cognitive impairment on the reliability of geriatric assessments in nursing homes
82. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow up from the nurses' health study
83. Decreased mortality in users of estrogen replacement therapy
84. The effect of postmenopausal estrogen therapy on bone density in elderly women
85. Hormone therapy to prevent disease and prolong life in postmenopausal women
86. Guidelines for counseling postmenopausal women about preventive hormone therapy
87. Gender differences in the treatment of behavior problems in Alzheimer's disease
88. Identifying complications of care using administrative data
89. Epidemiologic user of Medicare data
90. Methodological challenge and innovations in patient outcomes research
91. Parkinson's disease as a community health problem: Study in Norwegian nursing homes
92. Prevalence, clinical characteristics and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities
93. Predictors of nursing home residents' participation in activity programs
94. Association of the Resident Assessment Instrument (RAI) with changes in function, cognition and psychosocial status